SCHEMBL6509384

SCHEMBL6509384

CCOC(=O)COc1ccc(C=Cc2c([N+](=O)[O-])c(=O)n(C)c(=O)n2C)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
POLB P06746 1/20 0.78
NCOA1 Q15788 1/20 0.69
NCOA3 Q9Y6Q9 1/20 0.69
ALDH1A1 P00352 3/20 0.65
MAPK1 P28482 1/20 0.65
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
LMNA P02545 2/20 0.53
PTGS2 P35354 2/20 0.50
MITF O75030 1/20 0.50
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
NPSR1 Q6W5P4 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
NTSR1 P30989 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509381 1.00 MAPT (0.78) MAPTSMN1; SMN2POLBNCOA1NCOA3
SCHEMBL14506304 0.78 PTGS2 (0.78) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL9192509 0.78 PTGS2 (0.78) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL9192511 0.78 PTGS2 (0.78) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL20024754 0.76 GAA (0.66) MAPTSMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL6511560 0.76 MAPT (0.67) MAPTSMN1; SMN2POLBNCOA1NCOA3
SCHEMBL6511554 0.76 MAPT (0.67) MAPTSMN1; SMN2POLBNCOA1NCOA3
SCHEMBL6503720 0.76 MAPT (0.57) MAPTSMN1; SMN2POLBNCOA1NCOA3
SCHEMBL6503717 0.76 MAPT (0.57) MAPTSMN1; SMN2POLBNCOA1NCOA3
SCHEMBL24451139 0.75 MAPT (0.72) MAPTSMN1; SMN2POLBNCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070558-A1 6-Phenyldihydropyrrolopyrimidinedione derivatives ALMIRALL PRODESFARMA S.A. (ES) 2005-03-31 US disclosed
WO-2005026139-A1 NEMATICIDAL DIFLUOROALKENES BAYER CROPSCIENCE AG (DE) 2005-03-24 WO disclosed
EP-1465490-A2 NEMATICIDAL TRIFLUOROBUTENYL IMIDAZOLE THIOETHER DERIVATIVES Bayer CropScience AG (DE) 2004-10-13 EP disclosed
WO-2003106436-A1 NEMATICIDAL TETRAZOLE-CONTAINING TRIFLUOROBUTENES BAYER CROPSCIENCE AG (DE) 2003-12-24 WO disclosed
WO-2003049541-A2 NEMATICIDAL TRIFLUOROBUTENYL IMIDAZOLE THIOETHER DERIVATIVES BAYER CROPSCIENCE AG (DE) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070558-A1 6-Phenyldihydropyrrolopyrimidinedione derivatives ADORA1, ADORA2A, P2RY10 MAPT 4800/4885SMN1; SMN2 3868/4885POLB 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.